These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 1388899)

  • 21. Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir.
    Mujib S; Liu J; Rahman AKMN; Schwartz JA; Bonner P; Yue FY; Ostrowski MA
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28592534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What's new in HIV/AIDS? Neutralizing HIV antibodies: do they really protect?
    Jülg B; Goebel FD
    Infection; 2005 Oct; 33(5-6):405-7. PubMed ID: 16258878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficient neutralization of primary isolates by the plasma from HIV-1 infected Indian children.
    Prakash SS; Chaudhary AK; Lodha R; Kabra SK; Vajpayee M; Hazarika A; Bagga B; Luthra K
    Viral Immunol; 2011 Oct; 24(5):409-13. PubMed ID: 22004138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-1 cross-neutralizing antibodies in German HIV-1-infected patients do not correlate with an antibody-binding pattern against different HIV-1 isolates.
    Jurkiewicz E; Petry H; Sutor GC; Lang S; Schedel I; Hunsmann G
    AIDS; 1995 Jan; 9(1):91-3. PubMed ID: 7893448
    [No Abstract]   [Full Text] [Related]  

  • 25. Induction of complement-mediated lysis of HIV-1 by a combination of HIV-specific and HLA allotype-specific antibodies.
    Hildgartner A; Wilflingseder D; Gassner C; Dierich MP; Stoiber H; Bánki Z
    Immunol Lett; 2009 Sep; 126(1-2):85-90. PubMed ID: 19698750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.
    Ruppach H; Nara P; Raudonat I; Elanjikal Z; Rübsamen-Waigmann H; Dietrich U
    J Virol; 2000 Jun; 74(12):5403-11. PubMed ID: 10823844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of neutralizing antibodies in HIV infection.
    Humbert M; Dietrich U
    AIDS Rev; 2006; 8(2):51-9. PubMed ID: 16848273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody-dependent cellular cytotoxicity and neutralizing activity in sera of HIV-1-infected mothers and their children.
    Broliden K; Sievers E; Tovo PA; Moschese V; Scarlatti G; Broliden PA; Fundaro C; Rossi P
    Clin Exp Immunol; 1993 Jul; 93(1):56-64. PubMed ID: 8324904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of autologous neutralizing antibodies in the cerebrospinal fluid of HIV-1 infected individuals.
    von Gegerfelt A; Chiodi F; Keys B; Norkrans G; Hagberg L; Fenyö EM; Broliden K
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1133-8. PubMed ID: 1503825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification and characterization of broadly cross-reactive neutralizing antibodies in patients infected with HIV-1 B'/C recombinant (CRF07_BC).
    Bao MJ; Geng WQ; Cui HL; Zhang XL; Xu DB; Nian H; Dai D; Wang YN; Shang H
    Mol Med Rep; 2012 May; 5(5):1311-7. PubMed ID: 22344547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization.
    Spear GT; Takefman DM; Sharpe S; Ghassemi M; Zolla-Pazner S
    Virology; 1994 Nov; 204(2):609-15. PubMed ID: 7941328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutralizing antibody responses in patients with AIDS with neurologic complications.
    Beilke MA; Minagawa H; Stone G; Leon-Monzon M; Gibbs CJ
    J Lab Clin Med; 1991 Dec; 118(6):585-8. PubMed ID: 1744507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-HIV-1 antibodies trigger non-lytic complement deposition on infected cells.
    Dufloo J; Guivel-Benhassine F; Buchrieser J; Lorin V; Grzelak L; Dupouy E; Mestrallet G; Bourdic K; Lambotte O; Mouquet H; Bruel T; Schwartz O
    EMBO Rep; 2020 Feb; 21(2):e49351. PubMed ID: 31833228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Binding antibody to neutralizing epitope gp41 in HIV-1 subtype CRF 01_AE infection related to stage of disease.
    Srisurapanon S; Louisirirotchanakul S; Sumransurp K; Ratanasrithong M; Chuenchitra T; Jintakatkorn S; Wasi C
    Southeast Asian J Trop Med Public Health; 2005 Jan; 36(1):221-7. PubMed ID: 15906673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reconstitution and characterization of antibody repertoires of HIV-1-infected "elite neutralizers".
    Sun Z; Li J; Hu X; Shao Y; Zhang MY
    Antiviral Res; 2015 Jun; 118():1-9. PubMed ID: 25770672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Longitudinal study of serum neutralization of HIV-1 in infected plasma donors.
    Abelian AV; Saurya S; Ash S; Karpas A
    J Med Virol; 2001 Dec; 65(4):649-58. PubMed ID: 11745927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.
    Sanchez-Merino V; Fabra-Garcia A; Gonzalez N; Nicolas D; Merino-Mansilla A; Manzardo C; Ambrosioni J; Schultz A; Meyerhans A; Mascola JR; Gatell JM; Alcami J; Miro JM; Yuste E
    J Virol; 2016 Jun; 90(11):5231-5245. PubMed ID: 26984721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of a mouse/human chimeric monoclonal antibody (C beta 1) to a principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.
    Matsushita S; Maeda H; Kimachi K; Eda Y; Maeda Y; Murakami T; Tokiyoshi S; Takatsuki K
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1107-15. PubMed ID: 1380258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Broadly Neutralizing Antibody Responses in a Subset of HIV-1-Infected Individuals in Chennai, India.
    Hussain SI; Panneerselvam N; Solomon S; Solomon SS; Adam K; Chandrasekaran E; Montefiori DC; Pachamuthu B
    J Int Assoc Provid AIDS Care; 2017; 16(2):201-208. PubMed ID: 23422744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.